Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down prior to trading on Wednesday . The stock had previously closed at $26.43, but opened at $25.35. Nanobiotix shares last traded at $24.2620, with a volume of 19,067 shares.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. TD Cowen assumed coverage on shares of Nanobiotix in a report on Friday, February 6th. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Nanobiotix Price Performance

The stock’s 50-day moving average is $21.82 and its two-hundred day moving average is $17.74.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.